# Junta clínica — PT-pseudo_6c8ef835ea42 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_6c8ef835ea42",
  "pid": "PT-pseudo_6c8ef835ea42",
  "task": 1,
  "psa": 3.6,
  "age": 54,
  "months": 3,
  "pirads": "4",
  "psad": 0.119,
  "psav": 1.22,
  "psap": 2.0,
  "vol": 30.24,
  "dre": "Abnormal",
  "bx": "None",
  "cspca": 0.8235317,
  "medhx": "Not reported",
  "meds": "None",
  "notes": "PSA 3.6 ng/mL. PI-RADS 4. PSAD 0.12. Prostate volume 30 mL. DRE abnormal. csPCa 0.82.",
  "pmhx": [],
  "allergies": [],
  "vitals": {
    "weight": "78 kg",
    "height": "174 cm",
    "bmi": "25.8",
    "bp": "138/76 mmHg",
    "hr": "57 bpm",
    "smoking": "Current smoker (17 pack-yr)",
    "last_dental": "1 yr ago",
    "flu_vax": "Nov 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "19 Jan 2025",
  "enc_ref": "Dr. M. Jansen (GP)",
  "enc_type": "Follow-up - PSA + MRI",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Elevated prostate-specific antigen levels combined with an irregular digital rectal examination prompted this clinical assessment."
    },
    {
      "s": "History",
      "t": "A 54-year-old retired butcher entered the urological workup after a late-2023 PSA elevation, following a September 2021 baseline MRI at RUMC that noted a minor left-sided anomaly without pursuing a biopsy. Clinical records note an Abnormal DRE and a prior biopsy bucket of None. He denies lower urinary tract symptoms, recording an IPSS of zero, and reports no pelvic pain or hematuria. Married, he resides independently with an adult son living in close proximity. His emergency contact remains his daughter. He maintains a strict alcohol-free regimen and engages in light home weight-training twice weekly. Current smoker (17 pack-yr). No comorbid conditions or active medications complicate his baseline. Recent healthcare interactions included routine podiatry, a gastroenterology-ordered surveillance colonoscopy, and six physiotherapy sessions targeting chronic lower back stiffness. Commuting over an hour by train to reach this clinic, he values the allotted scheduling window."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: firm and irregular; mobility: fixed; asymmetry: pronounced in the left mid-gland region where a discrete nodule registers. General examination remains within normal limits, vital signs are stable, and no systemic pathology or lymphadenopathy emerges."
    }
  ],
  "occupation": "retired butcher",
  "marital": "Married",
  "living": "Lives alone; adult son nearby",
  "next_of_kin": "Adult daughter (primary contact)",
  "recent_other": [
    "Podiatry — routine foot care",
    "Gastroenterology — surveillance colonoscopy",
    "Physiotherapy — lower back, six sessions"
  ],
  "alcohol": "0 units / week (alcohol-free)",
  "exercise": "Light weight-training at home, 2x/week",
  "ipss": "IPSS score: 0/35 (mild LUTS)",
  "admin": "Patient travels 60+ min by train to clinic; allow buffer.",
  "mri_hospital": "Bravis Ziekenhuis",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_6c8ef835ea42
Task: 1

Encounter: Urology - outpatient on 19 Jan 2025.
Referrer: Dr. M. Jansen (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 54-year-old male
  - PSA: 3.6 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.119 ng/mL²
  - PSA velocity: 1.22 ng/mL/yr
  - Prior PSA: 2.0 ng/mL
  - Prostate volume: 30.24 mL
  - Months since last PSA: 3
  - DRE findings: Abnormal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8235317 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 3.6 ng/mL. PI-RADS 4. PSAD 0.12. Prostate volume 30 mL. DRE abnormal. csPCa 0.82.

Vitals: weight 78 kg, height 174 cm, BMI 25.8, BP 138/76 mmHg, HR 57 bpm. Smoking: Current smoker (17 pack-yr).

Chief complaint: Elevated prostate-specific antigen levels combined with an irregular digital rectal examination prompted this clinical assessment.

History: A 54-year-old retired butcher entered the urological workup after a late-2023 PSA elevation, following a September 2021 baseline MRI at RUMC that noted a minor left-sided anomaly without pursuing a biopsy. Clinical records note an Abnormal DRE and a prior biopsy bucket of None. He denies lower urinary tract symptoms, recording an IPSS of zero, and reports no pelvic pain or hematuria. Married, he resides independently with an adult son living in close proximity. His emergency contact remains his daughter. He maintains a strict alcohol-free regimen and engages in light home weight-training twice weekly. Current smoker (17 pack-yr). No comorbid conditions or active medications complicate his baseline. Recent healthcare interactions included routine podiatry, a gastroenterology-ordered surveillance colonoscopy, and six physiotherapy sessions targeting chronic lower back stiffness. Commuting over an hour by train to reach this clinic, he values the allotted scheduling window.

Physical examination: DRE — texture: firm and irregular; mobility: fixed; asymmetry: pronounced in the left mid-gland region where a discrete nodule registers. General examination remains within normal limits, vital signs are stable, and no systemic pathology or lymphadenopathy emerges.

Patient info: retired butcher; Married; Lives alone; adult son nearby.
Next of kin: Adult daughter (primary contact).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Light weight-training at home, 2x/week; IPSS score: 0/35 (mild LUTS).

Recent other appointments: Podiatry — routine foot care; Gastroenterology — surveillance colonoscopy; Physiotherapy — lower back, six sessions.
Admin: Patient travels 60+ min by train to clinic; allow buffer.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.82
  uncertainty  +/- 0.07 epistemic (95% band 0.68-0.95); among patients I cannot tell apart the outcome was 0.69 of 1.00 mixed
  reliability  HIGH ('firm' tier) — out-of-fold it was right 88% of the time over the 33 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: never biopsied. My criterion answers BIOPSY.

The criterion: sample when the mpMRI shows a PI-RADS 3 or higher lesion; defer at PI-RADS 1-2. In the labelled series this criterion matched the reading urologist in 24 of 24 cases in exactly this situation.

Like Expert 1, I have read ONLY the visible panel — not the mpMRI prose, the PSA trajectory, the
previous notes or the laboratory panel. Departing from me needs a specific finding from a document
somebody actually opened, named out loud; not a restatement of the panel numbers I already used.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 24 labelled men in this same situation (None prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 1.78: PI-RADS 4, PSA 4.8, PSAD 0.086, age 65, DRE Nodus -> BIOPSY (clear). He wrote: "P4 in patient 65 years."
  2. distance 1.99: PI-RADS 4, PSA 2.11, PSAD 0.058, age 59, DRE Normal -> BIOPSY (clear). He wrote: "P4 and LUTS symptoms. Note , low PSA."
  3. distance 2.40: PI-RADS 5, PSA 8.5, PSAD 0.368, age 56, DRE Nodus -> BIOPSY (clear). He wrote: "Biopsy-naive PIRADS 5 needs biopsy"

PRECEDENT: BIOPSY (weighted vote 1.00 for biopsy). Distance-weighted precedent is strong here (0.92 leave-one-out).

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 24 labelled traces in this situation (None prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes.
WHAT HE WEIGHS: bx=noted, fh=noted, age=important, dre=important, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines link PI-RADS scores to the decision to biopsy, noting that a threshold of PI-RADS $\ge 3$ is used to trigger biopsy. The guideline also suggests that adding perilesional sampling to targeted biopsy can mitigate drawbacks of the MRI pathway.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
Expert 1's suggestion of biopsy is not settled by the guideline because the guideline provides a threshold, and the decision for this patient must be made based on whether the PI-RADS 4 finding meets the specific criteria outlined in the guideline. The precedent suggests a biopsy in similar cases, but the guideline dictates the threshold application, which is a fact that no panel variable can override.

WHAT WE STILL NEED
The guideline requires confirmation of the PI-RADS score, which is known as 4 for this patient. The guideline also requires knowing the patient's prior biopsy status, which is known as 'None', to apply the risk-adapted matrix. The guideline also requires knowing the PSA density, which is known as 0.119 ng/mL$^2$, to apply the risk-adapted matrix. The guideline also requires knowing the patient's prior biopsy status, which is known as 'None', to apply the risk-adapted matrix.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case strongly suggests biopsy based on the PI-RADS score and the cohort data, but we must establish the specific guideline application for PI-RADS 4.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> What is the lesion size and zone of the PI-RADS 4 lesion?
  psa_trend (get_psa_trend) -> What is the trend of the serial PSA values?
  previous_notes (get_previous_notes) -> What is the management context regarding the prior biopsy status, number of biopsy sessions, and planned treatment?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the specific management context regarding the prior biopsy status ('None') as required by the risk-adapted matrix?

On the plan itself: Dropped 1 question(s) that asked for a value already printed on the panel: "What is the specific criterion outlined in the EAU guidelines that dictates the decision when the PI-RADS score is 4?".

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
Subject: Multiparametric MRI Prostate | Bravis Ziekenhuis | 15 Jan 2025
What is the lesion size and zone of the PI-RADS 4 lesion? The report states: "T2-weighted sequences reveal a 12 mm focus of hypointensity within the left mid-gland peripheral zone."
psa_trend
What is the trend of the serial PSA values? The trend shows: {"date": "Aug 2023", "val": 1.7}, {"date": "May 2024", "val": 2.5}, {"date": "Jan 2025", "val": 3.6}.
previous_notes
What is the management context regarding the prior biopsy status, number of biopsy sessions, and planned treatment? The notes indicate: "August 2023 screening returned a PSA of 1.3 ng/mL. Absence of urinary symptoms characterized the encounter." and "May 2024 tracking showed a PSA rise to 2.0 ng/mL. Repeat laboratory testing accompanied a urology referral for further assessment and imaging. Patient consent was documented."

WHAT I DID NOT OPEN
family-history anamnesis, because the decision hinges on the established clinical and imaging data already retrieved.

WHAT THIS SUPPORTS
FOR sampling this patient now
mpMRI report states: "Focal PI-RADS 4 lesion in the left mid-gland peripheral zone."
psa_trend shows: A rising trend from 1.7 ng/mL in Aug 2023 to 3.6 ng/mL in Jan 2025.
previous_notes indicate: A prior referral for further assessment and imaging in May 2024.

AGAINST sampling this patient now
previous_notes indicate: "prior biopsy bucket of None."

WHERE THIS LEANS
The imaging findings and rising PSA trend strongly support a biopsy, aligning with the cohort data and Expert 1's bid, though the specific EAU threshold application remains the outstanding question.
LEAN: biopsy

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 3.60 ng/mL over 3 points spanning 17 months; velocity +1.34 ng/mL per year; doubling time about 16 months.
PROJECTION at 6 months: 5.1 ng/mL, conformal 95% band 1.5-17.9.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report — the laboratory panel was not opened, so that block is imputed and my band is wider for it; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.80
  uncertainty  +/- 0.06 epistemic (95% band 0.69-0.91), of which 0.01 comes from values that had to be imputed
  reliability  HIGH ('firm' tier) — out-of-fold it was right 89% of the time over the 37 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.82  ('firm' tier)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.80  ('firm' tier, fusion_nolab)
  EXPERT-LIBRARY     BIOPSY, p(biopsy)=1.00  (k=3 precedents)
  EXPERT-COHORT      BIOPSY  (rule pirads_ge_3)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: cohort criterion (pirads_ge_3) — carried by EXPERT-COHORT.
PANEL ANSWER: BIOPSY. It matched the reading urologist in 24 of 24 labelled cases in exactly this situation (never biopsied).

Confidence the trace model expects here: clear. Weights it expects: bx=noted, fh=noted, age=important, dre=important, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened by the registrar—the radiology report, PSA trend, and previous notes—directly address the context required by the moderator's question regarding prior biopsy status and clinical trajectory.

ALIGNMENT WITH THE PANEL
The retrieved evidence strongly aligns with the PANEL-PROTOCOL's answer of BIOPSY, as the rising PSA trend and the PI-RADS 4 finding support the cohort criterion that fired the panel.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the specific management context regarding the prior biopsy status ('None') as required by the risk-adapted matrix? This context is partially addressed by the previous notes stating "prior biopsy bucket of None," which is the necessary input for the risk-adapted matrix.

WHAT CARRIES WEIGHT, AND WHY
The PI-RADS score of 4 is decisive as it triggered the cohort criterion. The rising PSA trend (1.7 to 3.6 ng/mL) indicates disease progression, and the prior biopsy status ('None') is crucial for applying the risk-adapted matrix as required by the guideline context.

MY SUGGESTION TO THE CHAIR
I suggest proceeding with a biopsy, as the retrieved data confirms the high-risk imaging finding and the rising PSA trend, which supports the panel's decision.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended because the PI-RADS score of 4, which is decisive, triggered the cohort criterion, which has a strong track record in this situation. This decision is further supported by the rising PSA trend, moving from 1.7 ng/mL to 3.6 ng/mL, and the patient's prior biopsy status being 'None'. The evidence converged on a biopsy, confirming the high-risk imaging finding and disease progression.

What carried weight: bx=noted, age=important, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes
